{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T16:19:24Z","timestamp":1793031564805,"version":"4.5.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010877","name":"Shenzhen Science and Technology Innovation Commission","doi-asserted-by":"publisher","award":["KQTD20200909113758004"],"award-info":[{"award-number":["KQTD20200909113758004"]}],"id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                    (PA) is a leading cause of hospital-acquired and ventilator-associated pneumonia. The multidrug-resistance (MDR) rate of PA is increasing making the management of PA a global challenge. Messenger RNA (mRNA) vaccines represent the most promising alternative to conventional vaccines and are widely studied for viral infection and cancer immunotherapy while rarely studied for bacterial infections. In this study, two mRNA vaccines encoding PcrV\u2013 the key component of the type III secretion system in\n                    <jats:italic>Pseudomonas<\/jats:italic>\n                    and the fusion protein OprF-I comprising outer membrane proteins OprF and OprI were constructed. The mice were immunized with either one of these mRNA vaccines or with the combination of both. Additionally, mice were vaccinated with PcrV, OprF, or the combination of these two proteins. Immunization with either mRNA-PcrV or mRNA-OprF-I elicited a Th1\/Th2 mixed or slighted Th1-biased immune response, conferred broad protection, and reduced bacterial burden and inflammation in burn and systemic infection models. mRNA-PcrV induced significantly stronger antigen-specific humoral and cellular immune responses and higher survival rate compared with the OprF-I after challenging with all the PA strains tested. The combined mRNA vaccine demonstrated the best survival rate. Moreover, the mRNA vaccines showed the superiority over protein vaccines. These results suggest that mRNA-PcrV as well as the mixture of mRNA-PcrV and mRNA-OprF-I are promising vaccine candidates for the prevention of PA infection.\n                  <\/jats:p>","DOI":"10.1038\/s41541-023-00672-4","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T01:01:39Z","timestamp":1684976499000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":93,"title":["Strong immune responses and protection of PcrV and OprF-I mRNA vaccine candidates against Pseudomonas aeruginosa"],"prefix":"10.1038","volume":"8","author":[{"given":"Xingyun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5982-8230","authenticated-orcid":false,"given":"Nino","family":"Rcheulishvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4793-2636","authenticated-orcid":false,"given":"Dimitri","family":"Papukashvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengfei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiwei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuehua","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3335-6794","authenticated-orcid":false,"given":"Peng George","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9480-9606","authenticated-orcid":false,"given":"Yunjiao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,25]]},"reference":[{"key":"672_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3389\/fcimb.2017.00039","volume":"7","author":"MF Moradali","year":"2017","unstructured":"Moradali, M. F., Ghods, S. & Rehm, B. H. Pseudomonas aeruginosa Lifestyle: A Paradigm for Adaptation, Survival, and Persistence. Front. Cell Infect. Microbiol. 7, 39 (2017).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"672_CR2","unstructured":"CDC. Pseudomonas aeruginosa. https:\/\/www.cdc.gov\/hai\/outbreaks\/pseudomonas-aeruginosa.html. (2021)."},{"key":"672_CR3","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1007\/s40265-021-01635-6","volume":"81","author":"D Reynolds","year":"2021","unstructured":"Reynolds, D. & Kollef, M. The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update. Drugs 81, 2117\u20132131 (2021).","journal-title":"Drugs"},{"key":"672_CR4","doi-asserted-by":"publisher","first-page":"665759","DOI":"10.3389\/fcimb.2021.665759","volume":"11","author":"RF Langendonk","year":"2021","unstructured":"Langendonk, R. F., Neill, D. R. & Fothergill, J. L. The Building Blocks of Antimicrobial Resistance in Pseudomonas aeruginosa: Implications for Current Resistance-Breaking Therapies. Front. Cell Infect. Microbiol. 11, 665759 (2021).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"672_CR5","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.biotechadv.2018.11.013","volume":"37","author":"Z Pang","year":"2019","unstructured":"Pang, Z., Raudonis, R., Glick, B. R., Lin, T. J. & Cheng, Z. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. Biotechnol. Adv. 37, 177\u2013192 (2019).","journal-title":"Biotechnol. Adv."},{"key":"672_CR6","doi-asserted-by":"publisher","unstructured":"Terreni, M., Taccani, M. & Pregnolato, M. New Antibiotics for Multidrug-Resistant Bacterial Strains: Latest Research Developments and Future Perspectives. Molecules 26 https:\/\/doi.org\/10.3390\/molecules26092671 (2021).","DOI":"10.3390\/molecules26092671"},{"key":"672_CR7","doi-asserted-by":"publisher","first-page":"909731","DOI":"10.3389\/fcimb.2022.909731","volume":"12","author":"S Reig","year":"2022","unstructured":"Reig, S., Le Gouellec, A. & Bleves, S. What Is New in the Anti-Pseudomonas aeruginosa Clinical Development Pipeline Since the 2017 WHO Alert? Front Cell Infect. Microbiol. 12, 909731 (2022).","journal-title":"Front Cell Infect. Microbiol."},{"key":"672_CR8","doi-asserted-by":"publisher","unstructured":"Sainz-Mejias, M., Jurado-Martin, I. & McClean, S. Understanding Pseudomonas aeruginosa-Host Interactions: The Ongoing Quest for an Efficacious Vaccine. Cells 9 https:\/\/doi.org\/10.3390\/cells9122617 (2020).","DOI":"10.3390\/cells9122617"},{"key":"672_CR9","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/j.1365-2249.2005.02925.x","volume":"142","author":"AW Zuercher","year":"2005","unstructured":"Zuercher, A. W. et al. Cellular immunity in healthy volunteers treated with an octavalent conjugate Pseudomonas aeruginosa vaccine. Clin. Exp. Immunol. 142, 381\u2013387 (2005).","journal-title":"Clin. Exp. Immunol."},{"key":"672_CR10","doi-asserted-by":"publisher","first-page":"11020","DOI":"10.1073\/pnas.0702403104","volume":"104","author":"G Doring","year":"2007","unstructured":"Doring, G., Meisner, C. & Stern, M. & Flagella Vaccine Trial Study, G. A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proc. Natl. Acad. Sci. USA 104, 11020\u201311025 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"672_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-2792-z","volume":"24","author":"C Adlbrecht","year":"2020","unstructured":"Adlbrecht, C. et al. Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients-a randomized clinical trial. Crit. Care 24, 74 (2020).","journal-title":"Crit. Care"},{"key":"672_CR12","doi-asserted-by":"publisher","first-page":"831","DOI":"10.2174\/138920312804871210","volume":"13","author":"M Galle","year":"2012","unstructured":"Galle, M., Carpentier, I. & Beyaert, R. Structure and function of the Type III secretion system of Pseudomonas aeruginosa. Curr. Protein Pept. Sci. 13, 831\u2013842 (2012).","journal-title":"Curr. Protein Pept. Sci."},{"key":"672_CR13","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/nrmicro2199","volume":"7","author":"AR Hauser","year":"2009","unstructured":"Hauser, A. R. The type III secretion system of Pseudomonas aeruginosa: infection by injection. Nat. Rev. Microbiol. 7, 654\u2013665 (2009).","journal-title":"Nat. Rev. Microbiol."},{"key":"672_CR14","first-page":"1983","volume":"218","author":"DE Tabor","year":"2018","unstructured":"Tabor, D. E. et al. Pseudomonas aeruginosa PcrV and Psl, the Molecular Targets of Bispecific Antibody MEDI3902, Are Conserved Among Diverse Global Clinical Isolates. J. Infect. Dis. 218, 1983\u20131994 (2018).","journal-title":"J. Infect. Dis."},{"key":"672_CR15","doi-asserted-by":"publisher","first-page":"781","DOI":"10.3389\/fimmu.2019.00781","volume":"10","author":"C Wan","year":"2019","unstructured":"Wan, C. et al. Rational Design of a Chimeric Derivative of PcrV as a Subunit Vaccine Against Pseudomonas aeruginosa. Front. Immunol. 10, 781 (2019).","journal-title":"Front. Immunol."},{"key":"672_CR16","doi-asserted-by":"publisher","first-page":"e96609","DOI":"10.1371\/journal.pone.0096609","volume":"9","author":"M Jiang","year":"2014","unstructured":"Jiang, M., Yao, J. & Feng, G. Protective effect of DNA vaccine encoding pseudomonas exotoxin A and PcrV against acute pulmonary P. aeruginosa Infection. PLoS One 9, e96609 (2014).","journal-title":"PLoS One"},{"key":"672_CR17","doi-asserted-by":"publisher","first-page":"6240","DOI":"10.1016\/j.vaccine.2006.05.077","volume":"24","author":"S Saha","year":"2006","unstructured":"Saha, S. et al. Multivalent DNA vaccine protects mice against pulmonary infection caused by Pseudomonas aeruginosa. Vaccine 24, 6240\u20136249 (2006).","journal-title":"Vaccine"},{"key":"672_CR18","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/1348-0421.12658","volume":"62","author":"Y Naito","year":"2018","unstructured":"Naito, Y. et al. The protective effects of nasal PcrV-CpG oligonucleotide vaccination against Pseudomonas aeruginosa pneumonia. Microbiol. Immunol. 62, 774\u2013785 (2018).","journal-title":"Microbiol. Immunol"},{"key":"672_CR19","doi-asserted-by":"publisher","first-page":"4384","DOI":"10.1128\/AAC.02643-14","volume":"58","author":"P Warrener","year":"2014","unstructured":"Warrener, P. et al. A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models. Antimicrob. Agents Chemother. 58, 4384\u20134391 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"672_CR20","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/ppul.22890","volume":"49","author":"CE Milla","year":"2014","unstructured":"Milla, C. E. et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatr. Pulmonol. 49, 650\u2013658 (2014).","journal-title":"Pediatr. Pulmonol."},{"key":"672_CR21","doi-asserted-by":"publisher","first-page":"629 e621","DOI":"10.1016\/j.cmi.2018.08.004","volume":"25","author":"SO Ali","year":"2019","unstructured":"Ali, S. O. et al. Phase 1 study of MEDI3902, an investigational anti-Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults. Clin. Microbiol. Infect. 25, 629 e621\u2013629.e626 (2019).","journal-title":"Clin. Microbiol. Infect."},{"key":"672_CR22","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1097\/CCM.0000000000001271","volume":"44","author":"H Katoh","year":"2016","unstructured":"Katoh, H. et al. IV Immunoglobulin for Acute Lung Injury and Bacteremia in Pseudomonas aeruginosa Pneumonia. Crit. Care Med. 44, e12\u2013e24 (2016).","journal-title":"Crit. Care Med."},{"key":"672_CR23","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1080\/21645515.2016.1209280","volume":"12","author":"M Kinoshita","year":"2016","unstructured":"Kinoshita, M. et al. The prophylactic effects of human IgG derived from sera containing high anti-PcrV titers against pneumonia-causing Pseudomonas aeruginosa. Hum. Vaccin. Immunother. 12, 2833\u20132846 (2016).","journal-title":"Hum. Vaccin. Immunother."},{"key":"672_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-022-04204-9","volume":"26","author":"J Chastre","year":"2022","unstructured":"Chastre, J. et al. Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial. Crit. Care 26, 355 (2022).","journal-title":"Crit. Care"},{"key":"672_CR25","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jmii.2016.08.014","volume":"51","author":"R Hassan","year":"2018","unstructured":"Hassan, R. et al. Immunization with outer membrane proteins (OprF and OprI) and flagellin B protects mice from pulmonary infection with mucoid and nonmucoid Pseudomonas aeruginosa. J. Microbiol. Immunol. Infect. 51, 312\u2013320 (2018).","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"672_CR26","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0928-8244(03)00072-5","volume":"37","author":"E Mansouri","year":"2003","unstructured":"Mansouri, E., Blome-Eberwein, S., Gabelsberger, J., Germann, G. & von Specht, B. U. Clinical study to assess the immunogenicity and safety of a recombinant Pseudomonas aeruginosa OprF-OprI vaccine in burn patients. FEMS Immunol. Med. Microbiol. 37, 161\u2013166 (2003).","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"672_CR27","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1128\/iai.42.3.1027-1033.1983","volume":"42","author":"LM Mutharia","year":"1983","unstructured":"Mutharia, L. M. & Hancock, R. E. W. Surface Localization of Pseudomonas-Aeruginosa Outer-Membrane Porin Protein-F by Using Monoclonal-Antibodies. Infect. Immunity 42, 1027\u20131033 (1983).","journal-title":"Infect. Immunity"},{"key":"672_CR28","doi-asserted-by":"publisher","first-page":"6551","DOI":"10.1128\/JB.180.24.6551-6556.1998","volume":"180","author":"D De Vos","year":"1998","unstructured":"De Vos, D. et al. Sequence diversity of the oprI gene, coding for major outer membrane lipoprotein I, among rRNA group I pseudomonads. J. Bacteriol. 180, 6551\u20136556 (1998).","journal-title":"J. Bacteriol."},{"key":"672_CR29","doi-asserted-by":"publisher","unstructured":"Mayeux, G. et al. Cell-free expression of the outer membrane protein OprF of Pseudomonas aeruginosa for vaccine purposes. Life Sci. Alliance 4 https:\/\/doi.org\/10.26508\/lsa.202000958 (2021).","DOI":"10.26508\/lsa.202000958"},{"key":"672_CR30","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","volume":"586","author":"F Krammer","year":"2020","unstructured":"Krammer, F. SARS-CoV-2 vaccines in development. Nature 586, 516\u2013527 (2020).","journal-title":"Nature"},{"key":"672_CR31","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/nature01096","volume":"419","author":"M Amoretti","year":"2002","unstructured":"Amoretti, M. et al. Production and detection of cold antihydrogen atoms. Nature 419, 456\u2013459 (2002).","journal-title":"Nature"},{"key":"672_CR32","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.cell.2022.03.044","volume":"185","author":"L Qu","year":"2022","unstructured":"Qu, L. et al. Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell 185, 1728\u20131744.e1716 (2022).","journal-title":"Cell"},{"key":"672_CR33","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1084\/jem.20171450","volume":"215","author":"N Pardi","year":"2018","unstructured":"Pardi, N. et al. Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J. Exp. Med. 215, 1571\u20131588 (2018).","journal-title":"J. Exp. Med."},{"key":"672_CR34","doi-asserted-by":"publisher","unstructured":"Killough, M., Rodgers, A. M. & Ingram, R. J. Pseudomonas aeruginosa: Recent Advances in Vaccine Development. Vaccines (Basel) 10 https:\/\/doi.org\/10.3390\/vaccines10071100 (2022).","DOI":"10.3390\/vaccines10071100"},{"key":"672_CR35","doi-asserted-by":"publisher","unstructured":"Malhotra, S., Hayes, D., Jr & Wozniak, D. J. Cystic Fibrosis and Pseudomonas aeruginosa: the Host-Microbe Interface. Clin. Microbiol. Rev. 32 https:\/\/doi.org\/10.1128\/CMR.00138-18 (2019).","DOI":"10.1128\/CMR.00138-18"},{"key":"672_CR36","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1172\/JCI200320365","volume":"112","author":"W Costerton","year":"2003","unstructured":"Costerton, W. et al. The application of biofilm science to the study and control of chronic bacterial infections. J. Clin. Invest. 112, 1466\u20131477 (2003).","journal-title":"J. Clin. Invest."},{"key":"672_CR37","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/cxo.12621","volume":"101","author":"D Subedi","year":"2018","unstructured":"Subedi, D., Vijay, A. K. & Willcox, M. Overview of mechanisms of antibiotic resistance in Pseudomonas aeruginosa: an ocular perspective. Clin. Exp. Optom. 101, 162\u2013171 (2018).","journal-title":"Clin. Exp. Optom."},{"key":"672_CR38","doi-asserted-by":"publisher","first-page":"20130433","DOI":"10.1098\/rstb.2013.0433","volume":"369","author":"B Greenwood","year":"2014","unstructured":"Greenwood, B. The contribution of vaccination to global health: past, present and future. Philos. Trans. R Soc. Lond. B Biol. Sci. 369, 20130433 (2014).","journal-title":"Philos. Trans. R Soc. Lond. B Biol. Sci."},{"key":"672_CR39","doi-asserted-by":"publisher","unstructured":"Kowalzik, F. et al. mRNA-Based Vaccines. Vaccines (Basel) 9 https:\/\/doi.org\/10.3390\/vaccines9040390 (2021).","DOI":"10.3390\/vaccines9040390"},{"key":"672_CR40","doi-asserted-by":"publisher","unstructured":"Wang, X. et al. Development of DNA Vaccine Candidate against SARS-CoV-2. Viruses 14 https:\/\/doi.org\/10.3390\/v14051049 (2022).","DOI":"10.3390\/v14051049"},{"key":"672_CR41","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.copbio.2021.09.016","volume":"73","author":"E Kon","year":"2022","unstructured":"Kon, E., Elia, U. & Peer, D. Principles for designing an optimal mRNA lipid nanoparticle vaccine. Curr. Opin. Biotechnol. 73, 329\u2013336 (2022).","journal-title":"Curr. Opin. Biotechnol."},{"key":"672_CR42","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","volume":"383","author":"EE Walsh","year":"2020","unstructured":"Walsh, E. E. et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N. Engl. J. Med. 383, 2439\u20132450 (2020).","journal-title":"N. Engl. J. Med."},{"key":"672_CR43","doi-asserted-by":"publisher","unstructured":"Liu, C. et al. Development of an LNP-Encapsulated mRNA-RBD Vaccine against SARS-CoV-2 and Its Variants. Pharmaceutics 14 https:\/\/doi.org\/10.3390\/pharmaceutics14051101 (2022).","DOI":"10.3390\/pharmaceutics14051101"},{"key":"672_CR44","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1038\/d41587-021-00023-5","volume":"39","author":"C Sheridan","year":"2021","unstructured":"Sheridan, C. First COVID-19 DNA vaccine approved, others in hot pursuit. Nat. Biotechnol. 39, 1479\u20131482 (2021).","journal-title":"Nat. Biotechnol."},{"key":"672_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01311-z","volume":"20","author":"Y Wang","year":"2021","unstructured":"Wang, Y. et al. mRNA vaccine: a potential therapeutic strategy. Mol. Cancer 20, 33 (2021).","journal-title":"Mol. Cancer"},{"key":"672_CR46","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/nyas.14739","volume":"1511","author":"J Cable","year":"2022","unstructured":"Cable, J. et al. Innovative vaccine approaches-a Keystone Symposia report. Ann. N Y Acad. Sci. 1511, 59\u201386 (2022).","journal-title":"Ann. N Y Acad. Sci."},{"key":"672_CR47","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","volume":"21","author":"AJ Pollard","year":"2021","unstructured":"Pollard, A. J. & Bijker, E. M. A guide to vaccinology: from basic principles to new developments. Nat. Rev. Immunol. 21, 83\u2013100 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"672_CR48","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1128\/IAI.00850-10","volume":"79","author":"L Fito-Boncompte","year":"2011","unstructured":"Fito-Boncompte, L. et al. Full virulence of Pseudomonas aeruginosa requires OprF. Infect. Immun. 79, 1176\u20131186 (2011).","journal-title":"Infect. Immun."},{"key":"672_CR49","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1093\/infdis\/146.6.770","volume":"146","author":"LM Mutharia","year":"1982","unstructured":"Mutharia, L. M., Nicas, T. I. & Hancock, R. E. Outer membrane proteins of Pseudomonas aeruginosa serotype strains. J. Infect. Dis. 146, 770\u2013779 (1982).","journal-title":"J. Infect. Dis."},{"key":"672_CR50","doi-asserted-by":"publisher","unstructured":"Sen-Kilic, E. et al. Defining the Mechanistic Correlates of Protection Conferred by Whole-Cell Vaccination against Pseudomonas aeruginosa Acute Murine Pneumonia. Infect. Immun. 89 https:\/\/doi.org\/10.1128\/IAI.00451-20 (2021).","DOI":"10.1128\/IAI.00451-20"},{"key":"672_CR51","doi-asserted-by":"publisher","first-page":"909","DOI":"10.2147\/DDDT.S189847","volume":"13","author":"A Hoggarth","year":"2019","unstructured":"Hoggarth, A. et al. Mechanistic research holds promise for bacterial vaccines and phage therapies for Pseudomonas aeruginosa. Drug. Des. Dev. Ther. 13, 909\u2013924 (2019).","journal-title":"Drug. Des. Dev. Ther."},{"key":"672_CR52","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.2147\/IDR.S244081","volume":"13","author":"MH Fakoor","year":"2020","unstructured":"Fakoor, M. H., Mousavi Gargari, S. L., Owlia, P. & Sabokbar, A. Protective Efficacy of the OprF\/OprI\/PcrV Recombinant Chimeric Protein Against Pseudomonas aeruginosa in the Burned BALB\/c Model. Infect. Drug Resist. 13, 1651\u20131661 (2020).","journal-title":"Infect. Drug Resist."},{"key":"672_CR53","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3389\/fimmu.2019.00594","volume":"10","author":"C Zhang","year":"2019","unstructured":"Zhang, C., Maruggi, G., Shan, H. & Li, J. Advances in mRNA Vaccines for Infectious Diseases. Front. Immunol. 10, 594 (2019).","journal-title":"Front. Immunol."},{"key":"672_CR54","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1080\/21645515.2019.1650999","volume":"16","author":"SM Baker","year":"2020","unstructured":"Baker, S. M., McLachlan, J. B. & Morici, L. A. Immunological considerations in the development of Pseudomonas aeruginosa vaccines. Hum. Vaccin. Immunother. 16, 412\u2013418 (2020).","journal-title":"Hum. Vaccin. Immunother."},{"key":"672_CR55","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s10989-021-10356-z","volume":"28","author":"J Dey","year":"2022","unstructured":"Dey, J. et al. Molecular Characterization and Designing of a Novel Multiepitope Vaccine Construct Against Pseudomonas aeruginosa. Int. J. Pept. Res. Ther. 28, 49 (2022).","journal-title":"Int. J. Pept. Res. Ther."},{"key":"672_CR56","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/1348-0421.12291","volume":"59","author":"M Zhang","year":"2015","unstructured":"Zhang, M. et al. Salmonella Typhimurium strain expressing OprF-OprI protects mice against fatal infection by Pseudomonas aeruginosa. Microbiol. Immunol. 59, 533\u2013544 (2015).","journal-title":"Microbiol. Immunol."},{"key":"672_CR57","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1046\/j.1365-2249.2002.01731.x","volume":"127","author":"C Moser","year":"2002","unstructured":"Moser, C. et al. Improved outcome of chronic Pseudomonas aeruginosa lung infection is associated with induction of a Th1-dominated cytokine response. Clin. Exp. Immunol. 127, 206\u2013213 (2002).","journal-title":"Clin. Exp. Immunol."},{"key":"672_CR58","doi-asserted-by":"publisher","unstructured":"Dzik, M., Aebisher, D., Olender, A. & Tabarkiewicz, J. Evaluation of Selected Parameters of the Specific Immune Response against Pseudomonas aeruginosa Strains. Cells 11 https:\/\/doi.org\/10.3390\/cells11010003 (2021).","DOI":"10.3390\/cells11010003"},{"key":"672_CR59","doi-asserted-by":"publisher","first-page":"e0117447","DOI":"10.1371\/journal.pone.0117447","volume":"10","author":"S Singh","year":"2015","unstructured":"Singh, S. et al. Granulocyte-macrophage colony stimulatory factor enhances the pro-inflammatory response of interferon-gamma-treated macrophages to Pseudomonas aeruginosa infection. PLoS One 10, e0117447 (2015).","journal-title":"PLoS One"},{"key":"672_CR60","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/j.1699-0463.1997.tb05092.x","volume":"105","author":"C Moser","year":"1997","unstructured":"Moser, C. et al. Chronic Pseudomonas aeruginosa lung infection is more severe in Th2 responding BALB\/c mice compared to Th1 responding C3H\/HeN mice. APMIS 105, 838\u2013842 (1997).","journal-title":"APMIS"},{"key":"672_CR61","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/j.jaci.2009.09.046","volume":"125","author":"HW Schroeder Jr","year":"2010","unstructured":"Schroeder, H. W. Jr & Cavacini, L. Structure and function of immunoglobulins. J. Allergy Clin. Immunol. 125, S41\u2013S52 (2010).","journal-title":"J. Allergy Clin. Immunol."},{"key":"672_CR62","doi-asserted-by":"publisher","first-page":"7201","DOI":"10.1016\/j.vaccine.2022.09.069","volume":"40","author":"AS Wolf","year":"2022","unstructured":"Wolf, A. S. et al. Quality of antibody responses by adults and young children to 13-valent pneumococcal conjugate vaccination and Streptococcus pneumoniae colonisation. Vaccine 40, 7201\u20137210 (2022).","journal-title":"Vaccine"},{"key":"672_CR63","doi-asserted-by":"publisher","unstructured":"Gajic, I. et al. Antimicrobial Susceptibility Testing: A Comprehensive Review of Currently Used Methods. Antibiotics (Basel) 11 https:\/\/doi.org\/10.3390\/antibiotics11040427 (2022).","DOI":"10.3390\/antibiotics11040427"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00672-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00672-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00672-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T02:04:09Z","timestamp":1684980249000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-023-00672-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,25]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["672"],"URL":"https:\/\/doi.org\/10.1038\/s41541-023-00672-4","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,25]]},"assertion":[{"value":"2 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"76"}}